1. Tacrolimus suppresses T-cell activation by binding an intracellular immunophilin. Which of the following correctly describes the downstream consequence of this binding event?

• A) The tacrolimus-immunophilin complex inhibits inosine monophosphate dehydrogenase, blocking de novo purine synthesis in activated T cells.
• B) The tacrolimus-FKBP12 complex inhibits calcineurin, preventing dephosphorylation of NFAT and blocking interleukin-2 gene transcription.
• C) The tacrolimus-immunophilin complex inhibits mTOR complex 1, arresting T-cell proliferation at the G1-to-S phase transition.
• D) The tacrolimus-cyclophilin complex blocks the interleukin-2 receptor alpha chain, preventing IL-2-driven clonal T-cell expansion.
• E) The tacrolimus-immunophilin complex suppresses nuclear factor kappa B, reducing transcription of multiple pro-inflammatory cytokine genes.

2. Both tacrolimus and cyclosporine are calcineurin inhibitors that converge on the same downstream target. Which statement correctly distinguishes the intracellular binding partners of these two agents?

• A) Tacrolimus binds cyclophilin, while cyclosporine binds FK506-binding protein 12 (FKBP12); both complexes then inhibit calcineurin.
• B) Tacrolimus binds mTOR complex 1 directly, while cyclosporine binds FKBP12 to form the complex that inhibits calcineurin.
• C) Both tacrolimus and cyclosporine bind FKBP12, but only the tacrolimus-FKBP12 complex is capable of inhibiting calcineurin.
• D) Tacrolimus binds FKBP12, while cyclosporine binds cyclophilin; both resulting drug-immunophilin complexes inhibit calcineurin.
• E) Cyclosporine binds FKBP12, while tacrolimus binds the IL-2 receptor alpha chain to block T-cell proliferation by a non-calcineurin mechanism.

3. Mycophenolate mofetil (MMF) is the most widely used antiproliferative agent in renal transplant maintenance immunosuppression. Which of the following correctly describes its mechanism of action and the basis for its lymphocyte selectivity?

• A) MMF is a prodrug hydrolyzed to mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH) in the de novo purine synthesis pathway; lymphocyte selectivity arises because T and B cells lack significant purine salvage pathway capacity and depend almost exclusively on de novo synthesis for proliferation.
• B) MMF is a prodrug converted to 6-mercaptopurine, which incorporates into replicating DNA and RNA to block lymphocyte proliferation; selectivity arises because lymphocytes divide more rapidly than other cell types and therefore accumulate the toxic nucleotide at higher concentrations.
• C) MMF directly inhibits calcineurin after hepatic conversion to its active form, blocking NFAT dephosphorylation and IL-2 transcription; selectivity arises because calcineurin is expressed at higher levels in lymphocytes than in non-immune cells.
• D) MMF inhibits xanthine oxidase in the de novo purine synthesis pathway, selectively impairing lymphocyte proliferation while sparing bone marrow progenitors that can compensate through enhanced thymidine synthesis.
• E) MMF blocks mTOR complex 1 after intestinal absorption, preventing G1-to-S phase progression in activated T cells; selectivity arises because mTORC1 is uniquely required for IL-2-driven T-cell clonal expansion rather than homeostatic T-cell maintenance.

4. A renal transplant recipient maintained on azathioprine develops a gout flare. The rheumatology team proposes initiating allopurinol. Which of the following best explains the danger of this combination and the preferred management strategy?

• A) Allopurinol inhibits thiopurine methyltransferase (TPMT), reducing azathioprine inactivation and causing accumulation of 6-mercaptopurine to hepatotoxic levels; azathioprine should be discontinued and mycophenolate mofetil initiated before allopurinol is started.
• B) Allopurinol competes with azathioprine for renal tubular secretion, dramatically increasing azathioprine plasma levels and causing nephrotoxicity in the transplanted kidney; the combination requires careful dose adjustment of both agents.
• C) Allopurinol inhibits xanthine oxidase, which is required to catabolize azathioprine to its inactive metabolites; co-administration leads to massive accumulation of thioguanine nucleotides and life-threatening myelosuppression — if the combination cannot be avoided, azathioprine dose must be reduced by approximately 75%, or azathioprine should be replaced with MMF.
• D) Allopurinol induces CYP3A4, accelerating azathioprine conversion to thioguanine nucleotides at a rate that overwhelms TPMT inactivation capacity; the result is rejection risk from insufficient immunosuppression rather than myelosuppression.
• E) Allopurinol blocks the purine salvage pathway in bone marrow progenitors, which synergizes with azathioprine's DNA incorporation to cause additive but predictable and manageable myelosuppression requiring weekly complete blood count monitoring.

5. A kidney transplant recipient on tacrolimus presents with a rising serum creatinine three weeks post-transplant. Tacrolimus trough level is 18 ng/mL (target 8–12 ng/mL). Renal biopsy shows vacuolization of tubular cells and afferent arteriolar hyalinosis without lymphocytic infiltration. Which mechanism best accounts for the acute reduction in graft GFR in this clinical context?

• A) Tacrolimus-mediated inhibition of mTOR complex 1 in mesangial cells impairs their contractile regulation of glomerular capillary surface area, reducing the filtration coefficient and GFR independently of renal blood flow.
• B) Tacrolimus-mediated calcineurin inhibition in podocytes disrupts NFAT-dependent nephrin gene transcription, causing slit diaphragm destabilization and proteinuria that reduces oncotic pressure and GFR.
• C) Tacrolimus-mediated suppression of NF-κB in tubular cells impairs prostaglandin E2 synthesis, removing afferent arteriolar vasodilatory tone and reducing single-nephron GFR.
• D) Tacrolimus-mediated TGF-β overproduction by renal interstitial fibroblasts drives progressive striped tubulointerstitial fibrosis, reducing the functional nephron mass available for filtration.
• E) Tacrolimus-mediated increased production of thromboxane A2 (TXA2) and endothelin causes afferent arteriolar vasoconstriction, reducing renal blood flow and glomerular filtration rate in the allograft.

6. Basiliximab is used as an induction agent in standard-risk renal transplant recipients. Which of the following correctly describes its mechanism and a key clinical distinction from antithymocyte globulin (ATG)?

• A) Basiliximab is a polyclonal antibody preparation that recognizes multiple T-cell surface antigens, causing complement-mediated T-cell depletion and profound lymphopenia; it is preferred over ATG in standard-risk recipients because its depletion is more targeted.
• B) Basiliximab is a chimeric monoclonal antibody targeting the IL-2 receptor alpha chain (CD25) on activated T cells; it prevents IL-2-driven clonal expansion without depleting T cells, producing adequate immunosuppression with substantially lower infection risk than the profound lymphopenia caused by ATG.
• C) Basiliximab is a humanized monoclonal antibody targeting the IL-2 receptor beta chain (CD122) on resting T cells; by blocking the intermediate-affinity IL-2 receptor, it inhibits homeostatic T-cell maintenance as well as activation-driven proliferation.
• D) Basiliximab binds CD20 on mature B cells, preventing B-cell-mediated alloantibody production in the early post-transplant period; it is preferred over ATG in standard-risk recipients because the B-cell threat to the graft exceeds the T-cell threat in the first post-transplant week.
• E) Basiliximab binds FKBP12 on activated T cells and inhibits calcineurin in a manner equivalent to tacrolimus, providing induction-level immunosuppression that is then transitioned to standard maintenance dosing; it is non-depleting because its calcineurin inhibition does not trigger complement activation.

7. Sirolimus and tacrolimus both bind the intracellular immunophilin FKBP12. Which of the following correctly explains why these agents produce fundamentally different immunosuppressive mechanisms despite sharing the same initial binding partner?

• A) Although both sirolimus and tacrolimus bind FKBP12, the sirolimus-FKBP12 complex inhibits mTOR complex 1 (mTORC1) rather than calcineurin; this arrests T-cell proliferation downstream of IL-2 receptor signaling at the G1-to-S phase transition, rather than blocking IL-2 production at the transcriptional level.
• B) Sirolimus binds FKBP12 at a different allosteric site than tacrolimus, causing FKBP12 to translocate to the nucleus and suppress IL-2 gene transcription directly rather than through calcineurin inhibition; the result is a deeper but more specific block than tacrolimus.
• C) Both sirolimus and tacrolimus inhibit calcineurin when bound to FKBP12, but sirolimus additionally inhibits mTORC1 through a direct interaction independent of FKBP12, making it a dual-target agent with broader immunosuppressive coverage.
• D) Sirolimus binds FKBP12 to form a complex that inhibits cyclophilin, preventing cyclosporine from accessing its target and thereby amplifying the calcineurin-inhibitory effect when used in combination regimens with calcineurin inhibitors.
• E) Sirolimus and tacrolimus both inhibit calcineurin through FKBP12, but sirolimus additionally suppresses NF-κB by preventing glucocorticoid receptor nuclear translocation, which is why mTOR inhibitors are used in steroid-sparing protocols.

8. Corticosteroids contribute to transplant immunosuppression through a mechanism that is distinct from calcineurin inhibitors and antiproliferative agents. Which of the following correctly describes the primary immunosuppressive mechanism of glucocorticoids in the transplant setting?

• A) Glucocorticoids inhibit IMPDH in the de novo purine synthesis pathway, complementing mycophenolate mofetil with an additive antiproliferative effect on T and B lymphocytes.
• B) Glucocorticoids bind the IL-2 receptor alpha chain on activated T cells, preventing IL-2-driven clonal expansion by a mechanism parallel to but independent of basiliximab.
• C) Glucocorticoids inhibit calcineurin by binding cyclophilin in the cytoplasm, forming a glucocorticoid-cyclophilin complex that complements the tacrolimus-FKBP12 calcineurin-inhibitory mechanism.
• D) Glucocorticoids bind the cytoplasmic glucocorticoid receptor (GR), causing nuclear translocation and direct interaction with nuclear factor kappa B (NF-κB) subunits that prevents NF-κB DNA binding and suppresses transcription of multiple pro-inflammatory cytokine genes including IL-1, IL-2, IL-6, TNF-α, and IFN-γ.
• E) Glucocorticoids deplete circulating T cells by triggering glucocorticoid receptor-mediated apoptosis in mature lymphocytes, producing rapid post-transplant lymphopenia that bridges the patient to effective maintenance immunosuppression.

9. Antithymocyte globulin (ATG) is used for induction in high-immunological-risk renal transplant recipients and for treatment of steroid-resistant T-cell mediated rejection. Which of the following correctly describes ATG's mechanism, a required clinical precaution, and its distinction from basiliximab?

• A) ATG is a humanized monoclonal antibody targeting CD25 that causes T-cell apoptosis through Fc-mediated cytotoxicity; unlike basiliximab, ATG requires two doses rather than a continuous infusion; no antiviral prophylaxis is required because the CD25 target is only expressed on activated, not resting, T cells.
• B) ATG is a murine monoclonal antibody targeting a single T-cell surface antigen (CD3), causing T-cell depletion by complement-mediated lysis; unlike basiliximab, it requires premedication with acetaminophen but not corticosteroids because its targeted mechanism does not trigger cytokine release syndrome.
• C) ATG is a polyclonal antibody preparation produced by immunizing rabbits or horses with human thymocytes, generating antibodies against a broad panel of T-cell surface antigens that cause complement-mediated and cell-mediated T-cell depletion; unlike basiliximab, it causes profound lymphopenia, which mandates antiviral prophylaxis for CMV reactivation with ganciclovir or valganciclovir.
• D) ATG is a polyclonal complement-activating antibody that selectively depletes CD25-positive activated T cells while sparing naive and memory T cells; unlike basiliximab, it requires lymphocyte count monitoring during infusion, but post-infusion CMV prophylaxis is not required in recipients who are CMV-seronegative donor/seronegative recipient pairs.
• E) ATG and basiliximab share the same molecular target (CD25) but differ in that ATG is polyclonal and basiliximab is monoclonal; because both agents block IL-2-driven T-cell expansion without depleting T cells, neither requires antiviral prophylaxis beyond standard immunosuppression-level coverage.

10. Post-transplant diabetes mellitus (PTDM) is a significant complication of transplant immunosuppression. Comparing tacrolimus and cyclosporine as calcineurin inhibitors, which of the following correctly explains why tacrolimus is associated with higher rates of PTDM despite both agents sharing the same downstream calcineurin-inhibitory mechanism?

• A) Tacrolimus causes higher rates of PTDM because it inhibits the hepatic CYP2C19 enzyme responsible for converting proinsulin to mature insulin, an effect that is more pronounced with tacrolimus than cyclosporine due to differences in hepatic distribution.
• B) Tacrolimus causes higher rates of PTDM because it induces peripheral insulin resistance through glucocorticoid receptor sensitization, an effect additive with the concurrent corticosteroid immunosuppression used in the same regimen.
• C) Tacrolimus causes higher rates of PTDM because it activates mTOR complex 1 in adipocytes as an off-target effect, driving fatty acid synthesis and visceral adiposity that produces secondary insulin resistance independent of direct beta-cell toxicity.
• D) Cyclosporine and tacrolimus produce equivalent rates of PTDM because they share identical calcineurin inhibition in pancreatic beta cells; the perceived difference is a confounding effect of tacrolimus being co-administered with higher corticosteroid doses in most protocols.
• E) Tacrolimus causes substantially higher rates of PTDM than cyclosporine because tacrolimus more potently inhibits the calcineurin-NFAT signaling pathway in pancreatic beta cells, which is required for glucose-stimulated insulin secretion; this direct beta-cell calcineurin inhibition impairs insulin secretory capacity in a manner additive with the insulin resistance caused by concurrent corticosteroids.

11. A renal transplant recipient asks about the expected side effect differences between tacrolimus and cyclosporine. Which of the following correctly pairs each calcineurin inhibitor with adverse effects that are specific to that agent rather than shared by both?

• A) Cyclosporine produces gingival hyperplasia and hirsutism through mechanisms not fully characterized; tacrolimus produces alopecia and substantially higher rates of post-transplant diabetes mellitus (PTDM) due to its more potent calcineurin-NFAT inhibition in pancreatic beta cells — these cosmetic and metabolic differences are agent-specific and do not occur with the alternative CNI.
• B) Cyclosporine produces alopecia and peripheral neuropathy, while tacrolimus produces gingival hyperplasia and hypertrichosis; both agents produce equivalent rates of PTDM because their shared calcineurin-inhibitory mechanism affects pancreatic beta cells identically.
• C) Tacrolimus produces gingival hyperplasia and hirsutism due to its cyclophilin-binding mechanism, while cyclosporine produces alopecia due to its FKBP12-binding mechanism; these adverse effects reflect the different hair follicle and gingival immunophilin subtypes targeted by each agent.
• D) Both cyclosporine and tacrolimus produce gingival hyperplasia at equivalent rates; the primary agent-specific distinction is that tacrolimus causes posterior reversible encephalopathy syndrome (PRES) while cyclosporine causes alopecia.
• E) Cyclosporine is associated with higher rates of PTDM than tacrolimus because cyclosporine more potently inhibits the calcineurin-NFAT pathway in pancreatic beta cells; tacrolimus is preferred in diabetic transplant candidates because it has lower beta-cell toxicity.

12. Long-term calcineurin inhibitor (CNI) use is a leading cause of late allograft dysfunction. Which of the following correctly distinguishes the mechanism and reversibility of chronic CNI nephrotoxicity from acute CNI nephrotoxicity?

• A) Chronic CNI nephrotoxicity results from long-term afferent arteriolar vasoconstriction reducing single-nephron GFR cumulatively over years; unlike acute CNI nephrotoxicity, the vasoconstriction becomes permanent due to smooth muscle hypertrophy, and dose reduction does not restore GFR.
• B) Chronic CNI nephrotoxicity results from long-term stimulation of transforming growth factor beta (TGF-β) signaling in renal tubular and interstitial cells, driving progressive striped tubulointerstitial fibrosis that is largely irreversible; it is distinguished from acute CNI nephrotoxicity — which is dose-related arteriolar vasoconstriction reversible with dose reduction — by its histological signature and irreversibility.
• C) Chronic CNI nephrotoxicity results from sustained calcineurin inhibition in glomerular endothelial cells, causing progressive thrombotic microangiopathy with platelet microthrombi in glomerular capillaries; it is distinguished from acute CNI nephrotoxicity by the presence of schistocytes and thrombocytopenia on peripheral blood smear.
• D) Chronic CNI nephrotoxicity is caused by progressive immune complex deposition in the mesangium driven by impaired regulatory T-cell function; prolonged calcineurin inhibition paradoxically activates complement-mediated mesangial injury that eventually leads to membranoproliferative-pattern glomerulonephritis.
• E) Chronic and acute CNI nephrotoxicity share the same mechanism — afferent arteriolar vasoconstriction mediated by TXA2 and endothelin — but chronic toxicity is distinguished clinically by the failure to respond to a single dose reduction; prolonged vasoconstriction eventually causes tubular atrophy through ischemia.

13. A renal transplant recipient on mycophenolate mofetil (MMF) is admitted for a urinary tract infection and treated with a broad-spectrum antibiotic course. The transplant team notes the patient may be at risk for reduced MMF efficacy during this admission. Which pharmacokinetic feature of MMF explains this concern?

• A) Broad-spectrum antibiotics induce CYP3A4 in the intestinal wall, accelerating the conversion of mycophenolate mofetil to its inactive glucuronide metabolite before systemic absorption can occur, thereby reducing peak MPA plasma concentrations.
• B) Broad-spectrum antibiotics competitively inhibit the intestinal esterases responsible for converting MMF prodrug to active mycophenolic acid (MPA), reducing the fraction of MMF that is activated to MPA after oral dosing.
• C) Broad-spectrum antibiotics compete with mycophenolic acid (MPA) for renal tubular secretion, increasing MPA renal clearance and reducing steady-state plasma MPA concentrations during antibiotic treatment.
• D) Mycophenolic acid (MPA) undergoes extensive enterohepatic recirculation: after glucuronidation in the liver to form MPAG (MPA glucuronide), MPAG is secreted in bile, deconjugated by intestinal bacteria to regenerate MPA, and reabsorbed; broad-spectrum antibiotics eliminate the gut flora responsible for this deconjugation step, disrupting the secondary MPA plasma peak and reducing total MPA exposure.
• E) Broad-spectrum antibiotics bind P-glycoprotein efflux transporters in the intestinal epithelium, redirecting MMF away from systemic absorption toward biliary excretion, reducing MPA bioavailability in a manner identical to the interaction between antibiotics and cyclosporine.

14. A renal transplant recipient is being converted from tacrolimus to sirolimus six months post-transplant due to progressive CNI nephrotoxicity on biopsy. The transplant team emphasizes that this conversion would not have been appropriate in the immediate post-operative period. Which mTOR inhibitor adverse effect explains this restriction and the underlying mechanism?

• A) mTOR inhibitors cause severe acute tubular necrosis in the newly transplanted kidney due to mTORC1 inhibition in proximal tubular epithelial cells, which disrupts ATP generation and ion transport during the vulnerable early post-transplant period.
• B) mTOR inhibitors cause profound early post-transplant lymphopenia by arresting lymphocyte progenitor proliferation in the bone marrow at the G1-to-S transition, producing additive immunosuppression that increases rejection risk in the immediate post-transplant period.
• C) mTOR inhibitors impair wound healing as a class effect because mTOR signaling is required for the proliferation of fibroblasts and endothelial cells needed for wound repair; perioperative mTOR inhibition increases anastomotic healing failure risk, wound dehiscence, and lymphocele formation around the graft, making these agents contraindicated for at least four to six weeks after transplant surgery.
• D) mTOR inhibitors cause severe post-transplant proteinuria by inhibiting mTORC1 in podocytes, disrupting the slit diaphragm integrity required for glomerular filtration barrier function; the proteinuric threshold is crossed in the immediate post-transplant period when single-nephron GFR is highest.
• E) mTOR inhibitors induce early acute antibody-mediated rejection by suppressing regulatory T-cell (Treg) expansion — Tregs require mTOR signaling for proliferation — thereby removing the immunosuppressive counterweight to alloreactive B-cell activation in the first post-transplant weeks.

15. A renal transplant recipient of Eastern European descent is started on azathioprine as the antiproliferative component of the maintenance regimen. Two weeks later, she develops severe pancytopenia with an absolute neutrophil count of 200 cells/mm³. Which of the following best explains the pharmacogenomic basis of this complication?

• A) The patient has homozygous loss-of-function variants in the CYP2C9 gene, impairing hepatic conversion of azathioprine to its active thioguanine nucleotide metabolites and producing an abnormal metabolite profile that is directly myelotoxic.
• B) The patient has a gain-of-function variant in the IMPDH2 gene, causing her lymphocytes to overproduce inosine monophosphate despite azathioprine-mediated pathway inhibition, generating excess thiopurine metabolites that accumulate in bone marrow progenitors.
• C) The patient has homozygous loss-of-function variants in the xanthine oxidase gene (XDH), preventing catabolism of azathioprine to its inactive metabolites and causing thioguanine nucleotide accumulation equivalent to the azathioprine-allopurinol interaction.
• D) The patient has an activating variant in the FKBP12 gene, causing aberrant azathioprine binding to FKBP12 and misdirecting thioguanine nucleotides to mTOR complex 1 inhibition in bone marrow progenitors rather than their intended lymphocyte target.
• E) The patient has homozygous loss-of-function variants in the thiopurine methyltransferase (TPMT) gene; TPMT is the principal enzyme inactivating 6-mercaptopurine (the active intermediate of azathioprine) through S-methylation, and TPMT deficiency causes accumulation of thioguanine nucleotides to levels that cause life-threatening myelosuppression at standard azathioprine doses.

16. A renal transplant recipient presents eight months post-transplant with rising creatinine. Biopsy demonstrates peritubular capillary C4d deposition, microvascular injury (peritubular capillaritis and glomerulitis), and absence of significant tubulitis. Donor-specific antibody (DSA) testing is strongly positive. Which treatment regimen is most appropriate for this diagnosis?

• A) Pulse methylprednisolone 500 mg intravenously daily for three consecutive days is the first-line treatment; if creatinine does not return toward baseline within five to seven days, antithymocyte globulin (ATG) is added for T-cell depletion.
• B) Plasmapheresis to physically remove circulating donor-specific antibodies, followed by intravenous immunoglobulin (IVIG) after each session to provide replacement immunoglobulins and modulate antibody effector mechanisms, combined with rituximab (anti-CD20 monoclonal antibody) to deplete B cells and suppress de novo DSA production.
• C) Basiliximab re-dosing to block IL-2-driven expansion of alloreactive T cells combined with mycophenolate mofetil dose escalation to suppress proliferating B cells; plasmapheresis is reserved for patients who fail this first-line B-cell-targeted strategy.
• D) Antithymocyte globulin (ATG) at standard rejection-treatment dosing (1.5 mg/kg/day for 10–14 days) is the appropriate first-line treatment because DSA-positive rejection is T-cell dependent; DSA titers fall spontaneously once the alloreactive T-cell help driving B-cell antibody production is eliminated.
• E) Sirolimus substitution for tacrolimus is initiated immediately, as mTOR inhibitor antiproliferative effects on B cells and plasma cells are the primary mechanism required to reduce DSA production; plasmapheresis is not indicated because antibody already bound to graft endothelium cannot be removed from the circulation.

17. A renal transplant recipient develops rising serum creatinine at week six post-transplant. Allograft biopsy reveals Banff grade IB T-cell mediated rejection (TCMR): significant tubulitis and interstitial inflammation without vascular involvement. Donor-specific antibody testing is negative. Which treatment approach is most appropriate?

• A) Pulse methylprednisolone 500 mg intravenously daily for three consecutive days is the first-line treatment for T-cell mediated rejection; if creatinine does not return toward baseline within five to seven days, the rejection is classified as steroid-resistant TCMR and antithymocyte globulin (ATG) is initiated at 1.5 mg/kg/day for 10–14 days.
• B) Rituximab (anti-CD20 monoclonal antibody, 375 mg/m²) combined with plasmapheresis is initiated immediately because DSA-negative rejection reflects subclinical antibody-mediated pathology that serology cannot detect; biopsy C4d staining is the definitive AMR marker and supersedes DSA testing.
• C) Basiliximab re-induction with two doses of 20 mg intravenously at days 0 and 4 is the appropriate treatment for acute TCMR because basiliximab's IL-2 receptor blockade prevents the ongoing IL-2-driven expansion of the alloreactive T cells identified on biopsy.
• D) Sirolimus is substituted for tacrolimus immediately, because mTOR inhibitor G1-to-S arrest is more effective than calcineurin inhibition for treating established alloreactive T-cell proliferation; tacrolimus is maintained for 48 hours as a bridge to prevent rebound rejection during the sirolimus loading period.
• E) Mycophenolate mofetil dose is doubled and a steroid taper is initiated over 14 days as a first-line strategy to reduce the alloreactive T-cell burden identified on biopsy; pulse corticosteroid therapy is reserved for Banff grade IIA or higher rejection because lower-grade rejection responds to immunosuppression optimization alone.

18. A renal transplant recipient stable on tacrolimus for two years is started on rifampin for treatment of latent tuberculosis reactivation. Two weeks later, the tacrolimus trough level is 2.1 ng/mL (target 5–8 ng/mL) and the creatinine is rising. Which mechanism explains this drug interaction and the resulting clinical risk?

• A) Rifampin competes with tacrolimus for binding to FKBP12, displacing tacrolimus from its intracellular target and reducing the effective calcineurin-inhibitory concentration even when total tacrolimus plasma levels remain therapeutic.
• B) Rifampin inhibits CYP3A4 in the intestinal wall and liver, dramatically increasing tacrolimus plasma levels through reduced first-pass metabolism; the supratherapeutic trough reflects rifampin-induced tacrolimus accumulation causing nephrotoxicity rather than true subtherapeutic immunosuppression.
• C) Rifampin chelates tacrolimus in the gastrointestinal tract before absorption, reducing tacrolimus bioavailability through direct drug binding; this pharmacokinetic interaction is equivalent to the absorption reduction seen with antacids and MMF.
• D) Rifampin is a potent inducer of CYP3A4 and P-glycoprotein (P-gp), dramatically increasing tacrolimus first-pass metabolism and intestinal efflux; the resulting subtherapeutic tacrolimus trough level removes adequate calcineurin-inhibitory immunosuppression and places the patient at acute rejection risk.
• E) Rifampin activates the nuclear pregnane X receptor (PXR), which upregulates FKBP12 expression in lymphocytes; higher FKBP12 concentrations compete with the tacrolimus-FKBP12 complex for calcineurin binding, reducing net calcineurin inhibition despite unchanged tacrolimus plasma levels.

19. A 26-year-old woman of childbearing potential receives a living-donor renal transplant and is started on tacrolimus, mycophenolate mofetil (MMF), and prednisone. At her first post-transplant clinic visit, the transplant pharmacist reviews the FDA Risk Evaluation and Mitigation Strategy (REMS) program applicable to her regimen. Which of the following correctly describes the reproductive safety requirement that applies specifically to MMF and the teratogenic risk it carries?

• A) The MMF REMS program requires monthly tacrolimus trough level monitoring in women of reproductive age because tacrolimus potentiates MMF teratogenicity through shared CYP3A4 metabolism, increasing active MPA plasma exposure during the first trimester.
• B) The MMF REMS program mandates that women of reproductive age receive the influenza and pneumococcal vaccines before becoming pregnant because MMF-mediated immunosuppression prevents adequate vaccine responses during pregnancy and the neonatal period.
• C) MMF carries an FDA REMS program due to its teratogenicity — it causes a characteristic embryopathy including external ear abnormalities, cleft lip and palate, and cardiac defects; women of reproductive age must use two forms of contraception while on MMF and for six weeks after discontinuation, and pregnancy testing is required before initiation.
• D) The MMF REMS program requires that women of reproductive age undergo TPMT genotyping before MMF initiation because thiopurine methyltransferase deficiency produces an MMF metabolite (mycophenolic acid glucuronide) that crosses the placental barrier and causes fetal azathioprine-type toxicity.
• E) MMF carries an FDA REMS program because it causes dose-dependent teratogenicity through IMPDH inhibition in fetal lymphocytes, producing congenital immunodeficiency; the REMS requires paternal contraception as the primary protective measure because MMF concentrates in seminal fluid.

20. A transplant team is selecting an induction agent for two different renal transplant candidates. Candidate 1 is a 45-year-old first-time transplant recipient with panel reactive antibody (PRA) of 8% and no prior sensitization. Candidate 2 is a 52-year-old patient receiving a second transplant with PRA of 65% and detected donor-specific antibodies (DSAs) against the incoming donor. Which induction strategy is appropriate for each candidate?

• A) Both candidates should receive antithymocyte globulin (ATG) because the risk of acute rejection always outweighs the infection risk of ATG in the perioperative period, regardless of immunological risk stratification; basiliximab is reserved for patients who develop ATG infusion reactions.
• B) Candidate 1 should receive basiliximab; Candidate 2 should also receive basiliximab because DSA-positive recipients carry antibody-mediated rejection risk that requires CD25 blockade rather than T-cell depletion — ATG is inappropriate in the presence of pre-formed DSAs because T-cell depletion worsens endothelial injury in DSA-positive grafts.
• C) Both candidates should receive basiliximab; ATG is no longer used in renal transplant induction because its T-cell depletion is associated with unacceptably high rates of post-transplant lymphoproliferative disorder (PTLD) regardless of immunological risk.
• D) Candidate 1 should receive ATG because first-time transplants require the deepest possible early immunosuppression to prevent sensitization; Candidate 2 should receive basiliximab because highly sensitized recipients are already producing DSAs and T-cell depletion does not address antibody-mediated allograft injury.
• E) Candidate 1 should receive basiliximab — standard immunological risk justifies the non-depleting CD25 blocker with lower infection risk; Candidate 2 should receive ATG — high immunological risk (repeat transplant, high PRA, detected DSA) requires deeper initial T-cell depletion that basiliximab alone cannot provide.

21. A renal transplant recipient converted from tacrolimus to sirolimus for CNI nephrotoxicity develops progressive dyspnea and dry cough four months after conversion. Chest computed tomography (CT) reveals bilateral ground-glass opacities. Infectious workup is negative. Which adverse effect of mTOR inhibitors explains this presentation, and which other class-related adverse effects should be monitored in this patient?

• A) The pulmonary findings represent sirolimus-mediated calcineurin inhibition in pulmonary macrophages, impairing alveolar clearance and causing lipoid pneumonia; associated adverse effects to monitor include tacrolimus-level rebound (since sirolimus partially displaces tacrolimus from FKBP12) and hyperkalemia from tubular calcineurin inhibition.
• B) The pulmonary findings represent non-infectious pneumonitis, a recognized class effect of mTOR inhibitors caused by mTORC1 inhibition in pulmonary interstitial cells; it requires sirolimus discontinuation and is associated with other mTOR inhibitor class adverse effects including severe hyperlipidemia requiring statin therapy, aphthous mouth ulcers, and proteinuria from podocyte mTORC1 inhibition.
• C) The pulmonary findings represent opportunistic Pneumocystis jirovecii pneumonia (PCP), which occurs at elevated rates with sirolimus because mTORC1 inhibition impairs CD8+ T-cell memory formation; the broader adverse effect profile of sirolimus is primarily infectious rather than metabolic.
• D) The pulmonary findings represent mTOR inhibitor-induced pulmonary hypertension from mTORC1-mediated upregulation of platelet-derived growth factor (PDGF) in pulmonary vascular smooth muscle; associated adverse effects to monitor include thrombocytopenia and capillary leak syndrome from PDGF excess.
• E) The pulmonary findings represent mTOR inhibitor-associated organizing pneumonia requiring high-dose pulse corticosteroids and immediate re-introduction of tacrolimus; unlike non-infectious pneumonitis, organizing pneumonia is an autoimmune manifestation of mTOR inhibitor use that worsens with drug discontinuation.

22. Accurate diagnosis of rejection type after renal transplantation requires biopsy with pathological analysis using the Banff classification. Which of the following correctly identifies the diagnostic triad required to establish a diagnosis of antibody-mediated rejection (AMR) and distinguishes it from the histological signature of T-cell mediated rejection (TCMR)?

• A) AMR is diagnosed by the presence of Banff grade IB tubulitis (significant mononuclear cell infiltration of tubular epithelium) and interstitial inflammation without vascular involvement; TCMR is distinguished by the presence of C4d deposition in the absence of tubulitis, reflecting complement activation by antibody in the peritubular capillaries rather than direct T-cell injury.
• B) AMR is diagnosed by the presence of lymphocytic intimal arteritis (endotheliitis, Banff v lesion) as the sole criterion, regardless of C4d staining or DSA status; TCMR is the diagnosis when lymphocytic tubulitis is present without arteritis, and the two diagnoses are mutually exclusive by definition.
• C) AMR requires only a positive donor-specific antibody (DSA) test; biopsy is confirmatory but not required for treatment initiation because DSA positivity alone — even in the absence of histological changes — mandates plasmapheresis, IVIG, and rituximab to prevent progression to overt rejection.
• D) AMR is diagnosed by the combination of microvascular injury (peritubular capillaritis or glomerulitis) and/or C4d deposition in peritubular capillaries, together with positive donor-specific antibodies (DSAs); TCMR is distinguished by the absence of DSAs and the presence of tubulitis and interstitial inflammation reflecting direct T-cell-mediated graft injury rather than antibody-driven complement and endothelial injury.
• E) AMR and TCMR share an identical histological signature in the Banff classification and are distinguished solely by the DSA test result: C4d-positive biopsy with positive DSA equals AMR; C4d-positive biopsy with negative DSA equals TCMR; the biopsy cellular infiltrate pattern does not contribute to the diagnostic classification.